Rogers OC - Search Results

1

Expression and purification of functional recombinant epitopes for the platelet antigens, PlA1 and PlA2.

Barron-Casella EA, Kickler TS, Rogers OC, Casella JF. Barron-Casella EA, et al. Among authors: rogers oc. Blood. 1994 Aug 15;84(4):1157-63. Blood. 1994. PMID: 7519475 Free article.

2

Construction of a human platelet alloantigen-1a epitope(s) within murine glycoprotein IIIa: identification of residues critical to the conformation of the antibody binding site(s).

Barron-Casella EA, Nebbia G, Rogers OC, King KE, Kickler TS, Casella JF. Barron-Casella EA, et al. Among authors: rogers oc. Blood. 1999 May 1;93(9):2959-67. Blood. 1999. PMID: 10216091 Free article.

3

Roles of erythropoietin, insulin-like growth factor 1, and unidentified serum factors in promoting maturation of purified murine erythroid colony-forming units.

Boyer SH, Bishop TR, Rogers OC, Noyes AN, Frelin LP, Hobbs S. Boyer SH, et al. Among authors: rogers oc. Blood. 1992 Nov 15;80(10):2503-12. Blood. 1992. PMID: 1421373 Free article.

4

Onset of erythropoietin response in murine erythroid colony-forming units: assignment to early S-phase in a specific cell generation.

Landschulz KT, Boyer SH, Noyes AN, Rogers OC, Frelin LP. Landschulz KT, et al. Among authors: rogers oc. Blood. 1992 May 15;79(10):2749-58. Blood. 1992. PMID: 1316785 Free article.

5

Erythropoietin receptors on murine erythroid colony-forming units: natural history.

Landschulz KT, Noyes AN, Rogers O, Boyer SH. Landschulz KT, et al. Blood. 1989 May 1;73(6):1476-86. Blood. 1989. PMID: 2540854 Free article.

6

An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response.

Rogers O, Yen H, Solomon A, Drake C, Denmeade S. Rogers O, et al. Prostate. 2019 Jul;79(10):1071-1078. doi: 10.1002/pros.23819. Epub 2019 May 6. Prostate. 2019. PMID: 31059598 Review.

7

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer.

Rogers OC, Antony L, Levy O, Joshi N, Simons BW, Dalrymple SL, Rosen DM, Pickering A, Lan H, Kuang H, Ranganath SH, Zheng L, Karp JM, Howard SP, Denmeade SR, Isaacs JT, Brennen WN. Rogers OC, et al. Mol Cancer Ther. 2020 Nov;19(11):2353-2362. doi: 10.1158/1535-7163.MCT-20-0227. Epub 2020 Sep 17. Mol Cancer Ther. 2020. PMID: 32943549 Free PMC article.

8

Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors.

Rogers OC, Rosen DM, Antony L, Harper HM, Das D, Yang X, Minn I, Mease RC, Pomper MG, Denmeade SR. Rogers OC, et al. Sci Rep. 2021 Jul 21;11(1):14925. doi: 10.1038/s41598-021-94534-5. Sci Rep. 2021. PMID: 34290365 Free PMC article.

9

PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer.

Rogers OC, Anthony L, Rosen DM, Brennen WN, Denmeade SR. Rogers OC, et al. Oncotarget. 2018 Apr 27;9(32):22436-22450. doi: 10.18632/oncotarget.25091. eCollection 2018 Apr 27. Oncotarget. 2018. PMID: 29854290 Free PMC article.

10

2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.

Akinboye ES, Rogers OC, Isaacs JT. Akinboye ES, et al. Among authors: rogers oc. Prostate. 2018 Jun;78(9):655-663. doi: 10.1002/pros.23494. Epub 2018 Mar 24. Prostate. 2018. PMID: 29572902 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters